In yesterday’s Wall Street session, Helius Medical Technologies Inc. (NASDAQ:HSDT) shares traded at $0.26, up 23.26% from the previous session.
As of this writing, 3 analysts cover Helius Medical Technologies Inc. (NASDAQ:HSDT). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $5.00 and a low of $1.00, we find $3.50. Given the previous closing price of $0.22, this indicates a potential upside of 1490.91 percent. HSDT stock price is now -3.18% away from the 50-day moving average and -78.24% away from the 200-day moving average. The market capitalization of the company currently stands at $8.00M.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
There are 0 analysts who have given it a hold rating, whereas 3 have given it a buy rating. Brokers who have rated the stock have averaged $3.17 as their price target over the next twelve months.
With the price target of $20, Noble Capital Markets recently initiated with Outperform rating for Helius Medical Technologies Inc. (NASDAQ: HSDT).
In other news, ANDREEFF DANE, President and CEO bought 80,041 shares of the company’s stock on Dec 16. The stock was bought for $19,946 at an average price of $0.25. Upon completion of the transaction, the President and CEO now directly owns 332,517 shares in the company, valued at $86454.42. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 23, President and CEO ANDREEFF DANE bought 89,300 shares of the business’s stock. A total of $27,835 was incurred on buying the stock at an average price of $0.31. This leaves the insider owning 308,003 shares of the company worth $80080.78. A total of 4.01% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in HSDT stock. A new stake in Helius Medical Technologies Inc. shares was purchased by NORTHERN TRUST CORP during the first quarter worth $6,000. TWO SIGMA SECURITIES, LLC invested $5,000 in shares of HSDT during the first quarter. In the first quarter, PRIVATE ADVISOR GROUP, LLC acquired a new stake in Helius Medical Technologies Inc. valued at approximately $4,000. SPIRE WEALTH MANAGEMENT acquired a new stake in HSDT for approximately $1,000. In total, there are 26 active investors with 5.20% ownership of the company’s stock.
Wednesday morning saw Helius Medical Technologies Inc. (NASDAQ: HSDT) opened at $0.2100. During the past 12 months, Helius Medical Technologies Inc. has had a low of $0.21 and a high of $5.79. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 15.20, and a quick ratio of 14.70. The fifty day moving average price for HSDT is $0.2737 and a two-hundred day moving average price translates $1.2179 for the stock.
The latest earnings results from Helius Medical Technologies Inc. (NASDAQ: HSDT) was released for Jun, 2022. According to the Medical Devices Company, earnings per share came in at -$0.97, beating analysts’ expectations of -$1.12 by 0.15. This compares to -$2.01 EPS in the same period last year. The company reported revenue of $0.2 million for the quarter, compared to $0.11 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 79.82 percent. For the current quarter, analysts expect HSDT to generate $170k in revenue.
Helius Medical Technologies Inc.(HSDT) Company Profile
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.
